Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Validation of claims‐based algorithms for psoriatic arthritis.

Tytuł :
Validation of claims‐based algorithms for psoriatic arthritis.
Autorzy :
Lee, Hemin
Ford, Julia A.
Jin, Yinzhu
Cho, Soo‐Kyung
Santiago Ortiz, Adrian J.
Tong, Angela Y.
Kim, Seoyoung C.
Pokaż więcej
Źródło :
Pharmacoepidemiology & Drug Safety; Apr2020, Vol. 29 Issue 4, p404-408, 5p
Czasopismo naukowe
Purpose An increasing number of new medications are being developed and approved for psoriatic arthritis (PsA). To generate real‐world evidence on comparative safety and effectiveness of these drugs, a claims‐based algorithm that can accurately identify PsA is greatly needed. Methods: To identify patients with PsA, we developed seven claims‐based algorithms based on a combination of diagnosis codes and medication dispensing using the claims data from Medicare parts A/B/D linked to electronic medical records (2012‐2014). Two physicians independently conducted a chart review using the treating physician's diagnosis of PsA as the gold standard. We calculated the positive predictive value (PPV) and 95% confidence intervals of each algorithm. Results: Of the total 2157 records identified by the seven algorithms, 45% of the records had relevant clinical data to determine the presence of PsA. The PPV of the algorithms ranged from 75.2% (algorithm 1: ≥2 diagnosis codes for PsA and ≥1 diagnosis code for psoriasis) to 88.6% (algorithm 7: ≥2 diagnosis codes for PsA with ≥1 code by rheumatologist and ≥1 dispensing for PsA medication). Having ≥2 diagnosis codes and ≥1 dispensing for PsA medications (algorithm 6) also had PPV of 82.4%. Conclusions: All seven claims‐based algorithms demonstrated a moderately high PPV of 75% to 89% in identifying PsA. The use of ≥2 diagnosis codes plus ≥1 prescription claim for PsA appears to be a valid and efficient tool in identifying PsA patients in the claims data, while broader algorithms based on diagnoses without a prescription claim also have reasonably good PPVs. [ABSTRACT FROM AUTHOR]
Copyright of Pharmacoepidemiology & Drug Safety is the property of John Wiley & Sons, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies